Nathan Kline Institute
Orangeburg, New York 10962
4 studies enrolling now · 23 studies all time
What they study most
Alzheimer Disease, Alzheimer's Disease, Autism Spectrum Disorder, Autism Spectrum Disorder (ASD), Cannabis Use, Depression, Depressive Disorder, Treatment-Resistant, Down Syndrome, Drug Use, Irritability Associated With Autism Spectrum Disorder, Major Depressive Disorder, Mental Illness
Studies at this site
- Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients — Recruiting now
- Neural and Psychiatric Consequences of Cannabis Use in Adolescents — Recruiting now
- Harm Reduction Services — Recruiting now
- Non-invasive Brain Stimulation Using Tdcs of the Third (of Many) Visual Pathways — Recruiting now
- Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD) — Running, not enrolling
- A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder — Completed
- A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD) — Completed
- Transcranial Near Infrared Radiation and Cerebral Blood Flow in Depression — Completed
- A Study of Gantenerumab in Participants With Mild Alzheimer Disease — Completed
- D-serine Augmentation of Neuroplasticity — Completed
- A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease — Completed
- Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine — Completed
- D-serine and Cognitive Remediation in Schizophrenia — Completed
- TDCS for Auditory Hallucinations in Schizophrenia — Completed
- D-serine for the Schizophrenia Prodrome — Completed
- Biomarkers in Schizophrenia — Completed
- High-Dose Oral Ziprasidone Versus Conventional Dosing in Participants With Residual Schizophrenia Symptoms — Completed
- A Multicenter Study of NAP (AL-108) in Schizophrenia — Completed
- Org 24448 (Ampakine) for Cognitive Deficits in Schizophrenia — Withdrawn before enrolling
- Treatment Study for Cognitive Deficits in Schizophrenia — Completed
- Vitamin E in Aging Persons With Down Syndrome — Status unconfirmed
- Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients — Completed
- Clozapine and Olanzapine Treatment of Aggression — Completed